强生：锐珂捷®埃万妥单抗注射液在中国上市

智通财经09-16 19:49

【强生：锐珂捷®埃万妥单抗注射液在中国上市】9月16日，强生公司宣布，锐珂捷®——埃万妥单抗注射液正式在中国上市，联合利珂®适用于携带表皮生长因子受体19号外显子缺失或21号外显子L858R置换突变的局部晚期或转移性晚期非小细胞肺癌成人患者的一线治疗。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2667885079?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-16 19:49","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2667885079","market":"us","top_or_hot":-1,"title":"强生：锐珂捷®埃万妥单抗注射液在中国上市","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【强生：锐珂捷®埃万妥单抗注射液在中国上市】</b>9月16日，强生公司宣布，锐珂捷®——埃万妥单抗注射液正式在中国上市，联合利珂®适用于携带表皮生长因子受体19号外显子缺失或21号外显子L858R置换突变的局部晚期或转移性晚期非小细胞肺癌成人患者的一线治疗。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>强生：锐珂捷®埃万妥单抗注射液在中国上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n强生：锐珂捷®埃万妥单抗注射液在中国上市\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【强生：锐珂捷®埃万妥单抗注射液在中国上市】</b>9月16日，强生公司宣布，锐珂捷®——埃万妥单抗注射液正式在中国上市，联合利珂®适用于携带表皮生长因子受体19号外显子缺失或21号外显子L858R置换突变的局部晚期或转移性晚期非小细胞肺癌成人患者的一线治疗。                </div>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0034235303.USD","symbol_name":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2667885079","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667885079","pubTimestamp":1789559357,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【强生：锐珂捷®埃万妥单抗注射液在中国上市】9月16日，强生公司宣布，锐珂捷®——埃万妥单抗注射液正式在中国上市，联合利珂®适用于携带表皮生长因子受体19号外显子缺失或21号外显子L858R置换突变的","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0426412945.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","VHT":"Vanguard Health Care ETF","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0426417589.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC","FHLC":"Fidelity MSCI Health Care Index","MEDX":"HORIZON KINETICS MEDICAL ETF","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IYH":"iShares U.S. Healthcare ETF","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2403377893.USD":"ALLIANZ SELECT INCOME AND GROWTH \"AM\" (USD) INC","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","IPOS":"Renaissance International IPO ETF","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","JNJ":"强生","LU1043141123.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) INC 2","BK4581":"高盛持仓","IXJ":"全球医疗业ETF-iShares","BK4532":"文艺复兴科技持仓","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","PJP":"INVESCO PHARMACEUTICALS ETF","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","RXL":"ProShares Ultra Health Care","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BMED":"iShares Health Innovation Active ETF","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","TRUH":"VanEck Healthcare TruSector ETF","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","GDOC":"Goldman Sachs Future Health Care Equity ETF","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","XLV":"健康照护类股ETF-SPDR","IHE":"iShares U.S. Pharmaceuticals ETF","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","IE000SO60NU8.SGD":"RQI GLOBAL \"I\" (SGDHDG) ACC A"},"translate_title":"Johnson & Johnson: Recco ® Evantumab injection launched in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IYH":0.6,"MEDX":0.6,"GDOC":0.6,"FHLC":0.6,"TRUH":0.6,"JDOC":0.6,"FTXH":0.6,"BMED":0.6,"RXL":0.6,"IXJ":0.6,"XLV":0.6,"IHE":0.6,"JNJ":1.5,"IPOS":1.5,"VHT":0.6,"PJP":0.6},"content_text":"【强生：锐珂捷®埃万妥单抗注射液在中国上市】9月16日，强生公司宣布，锐珂捷®——埃万妥单抗注射液正式在中国上市，联合利珂®适用于携带表皮生长因子受体19号外显子缺失或21号外显子L858R置换突变的局部晚期或转移性晚期非小细胞肺癌成人患者的一线治疗。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2667885079","isCrawlerRequest":true}